When to Hold Zanubrutinib
Hold zanubrutinib 3 days before and 7 days after minor and major surgical procedures, respectively, based on extrapolation from ibrutinib guidance, as zanubrutinib-specific perioperative data are not available in current guidelines. 1
Perioperative Management
The most clearly defined scenario for holding zanubrutinib comes from BTK inhibitor class guidance:
- Minor surgical procedures: Hold 3 days before and 3 days after the procedure 1
- Major surgical procedures: Hold 7 days before and 7 days after the procedure 1
This recommendation is extrapolated from ibrutinib data, as zanubrutinib shares the same mechanism of BTK inhibition and associated bleeding risk. The FDA label for zanubrutinib does not provide specific perioperative holding instructions, but the drug's antiplatelet effects warrant caution around invasive procedures. 2
Drug-Drug Interactions Requiring Temporary Discontinuation
Hold zanubrutinib during treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19, or reduce dose significantly, as ritonavir is a strong CYP3A4 inhibitor that dramatically increases zanubrutinib exposure. 3, 2
- Ritonavir causes similar drug interactions as other strong CYP3A4 inhibitors (e.g., ketoconazole) 3
- Either discontinue zanubrutinib or reduce dose until 3 days after completing nirmatrelvir/ritonavir therapy 3
- Alternative COVID-19 therapies without drug interactions (e.g., remdesivir) should be considered when possible 3
- The FDA label recommends dose reduction to 80 mg twice daily (or 80 mg once daily if already on reduced dose) when coadministered with strong CYP3A inhibitors 2
Hematologic Toxicity
Unlike tyrosine kinase inhibitors used in CML where specific holding thresholds are well-defined 4, 5, 6, zanubrutinib guidelines do not specify absolute neutrophil count or platelet thresholds that mandate drug holding. 2
However, clinical judgment should guide temporary discontinuation:
- Monitor for Grade 3-4 cytopenias, though the FDA label does not mandate specific holding parameters 2
- In real-world data, treatment discontinuation due to adverse events occurred in only 12.6% of zanubrutinib patients at 12 months, suggesting good tolerability 7
- Neutropenia rates are higher with zanubrutinib compared to ibrutinib, though Grade ≥3 infection rates remain similar 8
Cardiac Toxicity
Do not routinely hold zanubrutinib for new-onset atrial fibrillation; instead, manage the arrhythmia medically and consider switching to alternative therapy only if atrial fibrillation is recurrent and medically uncontrollable. 1, 9
- Atrial fibrillation rates are significantly lower with zanubrutinib (2.5%) compared to ibrutinib (10.1%) 10
- Real-world data confirm lower discontinuation rates due to cardiac events with zanubrutinib versus ibrutinib 7
- Consider non-warfarin anticoagulation for atrial fibrillation management, as warfarin should not be given concomitantly with BTK inhibitors 1
Severe Non-Hematologic Toxicity
Hold zanubrutinib for Grade 4 non-hematologic toxicity until toxicity improves to Grade 1 or better, then resume at reduced dose or switch to alternative therapy. 5
This guidance is extrapolated from dasatinib management in CML, as zanubrutinib-specific toxicity management algorithms are not detailed in current guidelines. 5
Hepatotoxicity
Hold zanubrutinib if transaminases exceed 5 times the upper limit of normal, based on idelalisib hepatotoxicity management principles for BTK/PI3K inhibitor class effects. 1
- The FDA label recommends dose modification in severe hepatic impairment but does not specify holding criteria for drug-induced hepatotoxicity 2
- Monitor hepatic function during treatment, particularly when combining with other potentially hepatotoxic agents 9
Important Caveats
- Avoid treatment-free intervals: When discontinuing zanubrutinib for disease progression, transition to next therapy as soon as possible, as progression may accelerate when BTK inhibitors are stopped 1
- Frailty considerations: In elderly patients (≥65 years), Clinical Frailty Scale >3 predicts higher discontinuation rates (29.2% vs 8.8% at 12 months), suggesting closer monitoring in frail patients 11
- Bleeding risk: Consider the benefit-risk ratio in patients requiring antiplatelet or anticoagulant therapies; avoid concurrent warfarin 1, 2